Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Clinical trial NCT03904108 · TERMINATED
Trial details
- NCT number
- NCT03904108
- Sponsor
- ROGER S KERESZTES MD
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-27
- Primary completion
- 2020-07-27
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.